Vanda Pharmaceuticals announces the publication of Efficacy and Safety of Iloperidone in Bipolar Mania: A Double-Blind, Placebo-Controlled Study in the Journal of Clinical Psychiatry

WASHINGTON, Jan. 17, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the publication of an article titled "Efficacy and Safety of Iloperidone in Bipolar Mania: A Double-Blind, Placebo-Controlled Study" in the Journal of Clinical Psychiatry.¹ The findings of this pivotal study have been submitted to the U.S. Food and Drug Administration (FDA) as part of Vanda's supplemental New Drug Application for Fanapt^® in the treatment of bipolar I disorder in adults. The FDA has set a Prescription Drug User Fee Act target action date of April 2, 2024 for its decision.

References

About Vanda Pharmaceuticals Inc.

Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on Twitter @vandapharma.

About Fanapt^®

For full U.S. Prescribing Information for Fanapt^®, including indication, Boxed Warnings and Important Safety Information, visit our Web site at www.fanapt.com.

Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-the-publication-of-efficacy-and-safety-of-iloperidone-in-bipolar-mania-a-double-blind-placebo-controlled-study-in-the-journal-of-clinical-psychiatry-302037494.html

SOURCE Vanda Pharmaceuticals Inc.